Vistagen reported a net loss primarily driven by research and development expenses for its CNS pipeline, including Phase 3 trials for fasedienol. The company maintains a cash runway to support operations through upcoming clinical milestones, though it currently generates no product revenue.
Vistagen reported financial results for its fiscal year 2027 second quarter ended September 30, 2026, and provided a corporate update on its fasedienol Phase 3 development plan for social anxiety disorder. The company highlighted constructive FDA feedback regarding its clinical trial design and the appointment of Dr. Douglas J. Williamson to its Board of Directors. Vistagen also implemented cost-management initiatives to prioritize capital for its late-stage neuroscience programs.
Term
Q2 2027
“Following our recent productive meeting with the FDA and our evaluation of the extensive body of efficacy, safety, and patient experience data generated throughout Phase 2 and Phase 3 development of fasedienol, we believe we have clarity on the potential regulatory pathways forward for fasedienol in social anxiety disorder”
Shawn Singh, President and Chief Executive Officer of Vistagen
“Recent alignment of our operating structure and capital resources with our late-stage development opportunities in both social anxiety disorder and menopausal hot flashes, position us to execute our plan to advance these programs while maintaining flexibility to create long-term shareholder value.”
Shawn Singh, President and Chief Executive Officer of Vistagen
Vistagen announced a productive Type C meeting with the FDA regarding the Phase 3 development path for its lead candidate, fasedienol, in social anxiety disorder (SAD). The FDA provided constructive feedback on using the Liebowitz Social Anxiety Scale (LSAS) as a primary endpoint and recommended incorporating interim assessments to evaluate long-term functional improvement.
Vistagen Therapeutics implemented a 31% reduction in its workforce to reduce operating expenses and preserve capital for its Phase 3 development of fasedienol. The company expects to incur approximately $1.0 million in one-time severance and termination costs while realizing annual savings of approximately $3.2 million in salary and benefits.